外周血和组织炎性细胞在鉴别PSA 4~10 ng/ml的前列腺癌和前列腺增生中的临床意义

马坦途, 李庆文, 刘贝贝, 等. 外周血和组织炎性细胞在鉴别PSA 4~10 ng/ml的前列腺癌和前列腺增生中的临床意义[J]. 临床泌尿外科杂志, 2019, 34(6): 434-437,440. doi: 10.13201/j.issn.1001-1420.2019.06.005
引用本文: 马坦途, 李庆文, 刘贝贝, 等. 外周血和组织炎性细胞在鉴别PSA 4~10 ng/ml的前列腺癌和前列腺增生中的临床意义[J]. 临床泌尿外科杂志, 2019, 34(6): 434-437,440. doi: 10.13201/j.issn.1001-1420.2019.06.005
MA Tantu, LI Qingwen, LIU Beibei, et al. Clinical significance of serum and tissue inflammatory cells for differentiating prostate cancer from benign prostatic hyperplasia with PSA 4-10 ng/ml[J]. J Clin Urol, 2019, 34(6): 434-437,440. doi: 10.13201/j.issn.1001-1420.2019.06.005
Citation: MA Tantu, LI Qingwen, LIU Beibei, et al. Clinical significance of serum and tissue inflammatory cells for differentiating prostate cancer from benign prostatic hyperplasia with PSA 4-10 ng/ml[J]. J Clin Urol, 2019, 34(6): 434-437,440. doi: 10.13201/j.issn.1001-1420.2019.06.005

外周血和组织炎性细胞在鉴别PSA 4~10 ng/ml的前列腺癌和前列腺增生中的临床意义

  • 基金项目:

    国家自然科学基金青年基金项目资助(编号81702495)

    安徽省自然科学基金青年科学基金项目资助(编号1808085QH279)

详细信息
    通讯作者: 郭园园,E-mail:guoshoahua111@163.com
  • 中图分类号: R737.25

Clinical significance of serum and tissue inflammatory cells for differentiating prostate cancer from benign prostatic hyperplasia with PSA 4-10 ng/ml

More Information
  • 目的:评价外周血和前列腺组织炎性细胞在鉴别前列腺特异性抗原(PSA)4~10 ng/ml的前列腺癌(PCa)和良性前列腺增生(BPH)中的临床意义。方法:回顾性分析我院2013年10月~2018年10月PSA水平4~10 ng/ml的PCa和BPH患者共45例,其中PCa组患者20例,BPH组患者25例。PCa组患者行前列腺癌根治术后病理确诊,BPH组患者行耻骨上经膀胱前列腺摘除术或经尿道前列腺电切术(TURP)后病理确诊。所有患者在行前列腺穿刺活检术前检测血常规,记录患者外周血中WBC、中性粒细胞、淋巴细胞和单核细胞计数,分析外周血淋巴细胞与单核细胞比率(LMR)、中性粒细胞与单核细胞比率(NMR)和中性粒细胞与淋巴细胞比率(NLR)等。同时收集患者术后病理石蜡切片,采用免疫组织化学(IHC)染色法检测前列腺组织中炎性细胞表达情况。结果:PCa组和BPH组患者外周血白细胞、中性粒细胞和淋巴细胞计数等指标比较差异无统计学意义。PCa组单核细胞计数明显低于BPH组,差异有统计学意义(P<0.05)。两组LMR、NMR和NLR值比较差异无统计学意义。两组淋巴细胞和中性粒细胞表达比较差异无统计学意义,但BPH组单核细胞标志物CD14表达高于PCa组,差异有统计学意义(P<0.05)。结论:检测外周血和组织中单核细胞计数有助于诊断PSA浓度4~10 ng/ml的PCa患者。
  • 加载中
  • [1]

    Siegel R L, Miller K D, Jemal A.Cancer statistics, 2018[J].CA Cancer J Clin, 2018, 68 (1):7-30.

    [2]

    Loeb S, Bjurlin M A, Nicholson J, et al.Overdiagnosis and overtreatment of prostate cancer[J].Eur Urol, 2014, 65 (6):1046-1055.

    [3]

    Bishayee A.The role of inflammation and liver cancer[J].Adv Exp Med Biol, 2014, 816:401-435.

    [4]

    Kundu J K, Surh Y J.Inflammation:gearing the journey to cancer[J].Mutat Res, 2008, 659 (1-2):15-30.

    [5]

    Wang K, Karin M.Tumor-Elicited Inflammation and Colorectal Cancer[J].Adv Cancer Res, 2015, 128:173-196.

    [6]

    Platz E A, Kulac I, Barber J R, et al.A prospective study of chronic inflammation in benign prostate tissue and risk of prostate cancer:linked PCPT and SELECT cohorts[J].Cancer Epidemiol Biomarkers Pre, 2017, 26 (10):1549-1557.

    [7]

    Arthur R, Williams R, Garmo H, et al.Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study[J].Int J Cancer, 2018, 142 (11):2254-2262.

    [8]

    Oh J J, Kwon O, Lee J K, et al.Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy[J].Asian J Androl, 2016, 18 (6):937-941.

    [9]

    Sun Z, Ju Y, Han F, et al.Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer[J].J Clin Lab Anal, 2018.

    [10]

    Kaynar M, Yildirim M E, Gul M, et al.Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio[J].Cancer biomarkers, 2015, 15 (3):317-323.

    [11]

    Chen R, Huang Y, Cai X, et al.Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml[J].PLoS One, 2015, 10 (6):e0130308.

    [12]

    Xu N, Wu Y P, Chen D N, et al.Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?[J].J Cancer Res Clin Oncol, 2018, 144 (5):987-995.

    [13]

    Gurel B, Lucia M S, Thompson I M Jr, et al.Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial[J].Cancer Epidemiol Biomarkers Prev, 2014, 23 (5):847-856.

    [14]

    Vasavada S R, Dobbs R W, Kajdacsy-Balla A A, et al.Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk:A Meta-Analysis[J].J Urol, 2018, 199 (5):1174-1181.

    [15]

    Ceylan Y, Günlüsoy B, Degirmenci T, et al.Neutrophil-to-lymphocyte and neutrophil-to-monocyte rates in the decision for a prostate re-bopsy in patients with a previous benign pathology and consistently 2.5-10 ng/ml PSA value[J].Arch Esp Urol, 2016, 69 (9):627-635.

    [16]

    Elzanaty S, Rezanezhad B, Borgquist R.Association between PSA Levels and Biomarkers of Subclinical Systemic Inflammation in Middle-Aged Healthy Men from the General Population[J].Curr Urol, 2016, 9 (3):148-152.

    [17]

    Gallo L.The Effect of a Pure Anti-inflammatory Therapy on Reducing Prostate-specific Antigen Levels in Patients Diagnosed With a Histologic Prostatitis[J].Urology, 2016, 94:198-203.

  • 加载中
计量
  • 文章访问数:  201
  • PDF下载数:  125
  • 施引文献:  0
出版历程
收稿日期:  2018-10-23

目录